Biotechnology

Aldeyra Therap

Aldeyra Therapeutics released FY2026 Q1 earnings on May 7 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.0572 (forecast USD -0.0975)

Aldeyra Therapeutics released FY2025 annual earnings on February 27 (EST), actual revenue USD 0 (forecast USD 24.25 M), actual EPS USD -0.5635 (forecast USD -0.2633)

Aldeyra Therapeutics released FY2025 Q4 earnings on February 27 (EST), actual revenue USD 0 (forecast USD 24.25 M), actual EPS USD -0.1073 (forecast USD 0.1583)

Aldeyra Therapeutics released FY2025 9 Months Earnings on November 5, 2025 (EST), actual revenue USD 0, actual EPS USD -0.4584

Aldeyra Therapeutics released FY2025 Q3 earnings on November 5, 2025 (EST), with actual revenue of USD 0 and EPS of USD -0.1278 (forecast EPS USD -0.245)

Aldeyra Therapeutics Ends ADX-629 Development Focusing on Next-Gen Candidates

Aldeyra Therapeutics Inc. reports positive results for its drug in hepatitis trial

Aldeyra Therapeutics released FY2025 Q2 earnings on August 7 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1626 (forecast USD -0.2433)

Aldeyra Therap released FY2025 Semi-Annual earnings on August 7 (EST), actual revenue USD 0, actual EPS USD -0.3284

Aldeyra's Dry Eye Drug Reproxalap NDA Accepted by FDA

ALDEYRA THERAPEUTICS Receives FDA SPA Agreement for ADX-2191 Clinical Trial

Aldeyra Therapeutics Resubmits Dry Eye Drug Application

Aldeyra Therapeutics Holds Annual Shareholder Meeting

Aldeyra Therapeutics to Participate in Jefferies Global Healthcare Conference

HC Wainwright Raises Aldeyra Therapeutics EPS Forecast

Aldeyra Therap released FY2025 Q1 earnings on May 14 (EST), actual revenue USD 0 (forecast USD -666.67 K), actual EPS USD -0.1658 (forecast USD -0.28)

Aldeyra Therapeutics Inc plans to resubmit new drug application in 2025

Aldeyra Therapeutics Inc. to Announce Topline Results for Reproxalap Dry Eye Disease Phase 3 Clinical Trial

Pomerantz LLP Investigates Aldeyra Investor Claims

Securities Firm Investigates Aldeyra Therapeutics

Netcapital

Agape ATP

Tradr 2X Long QBTS Daily ETF

Akanda

Defiance Daily Target 2X Long RGTI ETF

PicoCELA

Tradr 2X Long RGTI Daily ETF

Co-Diagnostics

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NewGenIvf

ALDX

Pomerantz Law Firm has filed a class action lawsuit against Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for alleged securities fraud. Investors who suffered losses are encouraged to contact the firm by May 29, 2026, to be appointed as Lead Plaintiff. The lawsuit follows a significant stock price drop after Aldeyra received a Complete Response Letter from the FDA regarding its investigational drug for dry eye disease, citing insufficient evidence of efficacy.

prnewswire

15:10 ETINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming Deadlines - ALDX

Faruqi & Faruqi, LLP is investigating claims against Aldeyra Therapeutics (ALDX) and reminds investors of the May 29, 2026 deadline to seek lead plaintiff status in a federal securities class action. The lawsuit alleges that Aldeyra made misleading statements regarding its drug candidate reproxalap, leading to significant investor losses after the FDA rejected its NDA due to insufficient evidence of efficacy. Investors who suffered losses are encouraged to contact the firm for legal options.

09:13 ETALDX EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026

Rosen Law Firm urges investors of Aldeyra Therapeutics, Inc. who purchased securities between November 3, 2023, and March 16, 2026, to secure counsel before the May 29, 2026, lead plaintiff deadline in a securities class action. Investors may be entitled to compensation without upfront fees. The lawsuit claims misleading statements regarding clinical trial results harmed investors. For more information, contact Phillip Kim, Esq. at 866-767-3653 or via email.

PR Newswire

ROSEN, A LEADING LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX

Faruqi & Faruqi, LLP is investigating potential claims against Aldeyra Therapeutics (NASDAQ: ALDX) and reminds investors of the May 29, 2026 deadline to seek lead plaintiff status in a federal securities class action. The lawsuit alleges that Aldeyra made misleading statements regarding its drug candidate reproxalap, leading to a significant stock price drop after the FDA rejected its NDA due to insufficient evidence of efficacy. Investors who suffered losses between November 3, 2023, and March 16, 2026, are encouraged to contact the firm for legal options.

11:35 ETALDX INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026

Rosen Law Firm has filed a securities fraud class action lawsuit against Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for investors who purchased securities between November 3, 2023, and March 16, 2026. Investors may be entitled to compensation without upfront fees. The lead plaintiff deadline is May 29, 2026. The lawsuit alleges that Aldeyra made misleading statements regarding the clinical trials of its drug candidate, reproxalap, leading to investor damages. Interested parties can contact the firm for more information on joining the class action.

19:01 ETALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm

Rosen Law Firm has filed a securities fraud class action lawsuit against Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for investors who purchased securities between November 3, 2023, and March 16, 2026. Investors may be entitled to compensation without upfront fees. The lead plaintiff deadline is May 29, 2026. The lawsuit alleges that Aldeyra made misleading statements regarding the clinical trials of its drug candidate reproxalap, leading to investor damages when the truth emerged. Interested investors can contact the firm for more information.

14:43 ETALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm

ABBV

Aldeyra Therapeutics has updated its corporate overview regarding reproxalap, revealing standardized efficacy estimates from trials and interpretations of FDA positions. Key points include a Complete Response Letter from the FDA due to insufficient evidence of efficacy, with a Type A meeting scheduled for Q2 2026. The company also outlined an exclusive option with AbbVie involving $100M upfront, milestone payments, and a profit split. Additionally, Aldeyra provided updates on its pipeline, with several trials expected to initiate in 2026 and a cash runway extending into 2028.

TradingView

Abbvie

Aldeyra Therapeutics updates reproxalap NDA data, outlines FDA meeting and AbbVie option

Pomerantz LLP has filed a class action lawsuit against Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for alleged securities fraud. Investors who suffered losses are encouraged to contact the firm by May 29, 2026, to be appointed as Lead Plaintiff. The lawsuit follows a significant stock price drop after Aldeyra received a Complete Response Letter from the FDA regarding its investigational drug for dry eye disease, citing insufficient evidence of efficacy. Pomerantz LLP specializes in corporate and securities class litigation.

19:42 ETINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming Deadlines - ALDX

Aldeyra Therap(ALDX.US)